الفهرس 
Title : Impact of direct acting anti HCV drugs (DAAs) on renal function indices in patients with chronic Hepatitis C virus (HCV) infection
ContantsOnly 14 pages are availabe for public view
 |  | from | 93 |  |  |
| | | from | 93 | | |
Abstract
Background and aim Hepatitis C virus (HCV) infection is a global health problem. The changes in renal function indices after receiving direct acting antiviral drugs (DAAs) in chronic HCV infected patients with normal renal functions is not well defined. The aim of our study is to evaluate the changes in renal function indices in Egyptian patients with chronic HCV infection following treatment with DAAs- based therapy. Patients and methods This is a prospective study included 159 Egyptian patients with chronic HCV infection who received DAAs-based therapy at Viral Hepatitis Specialized Treatment Center at Kasr Al-Ainy University Hospital according to the guidelines of the National Committee for Control of Viral Hepatitis (NCCVH) in the period from October 2017 to November 2018. The received regimens were SOF/DAC±RBV and one patient received Querevo/SOF/RBV. Relevant laboratory tests were obtained before initiation of therapy, after 4 and 8 weeks of therapy, at the end of treatment (EOT) and 12 weeks after EOT; SVR12significance